
Keywords: Chemoprevention; Drug; Esophageal Cancer; Pharmacoepidemiology; Statin; EAC; esophageal adenocarcinoma; GERD; gastroesophageal reflux disease; HMG-CoA; 3-hydroxy-3-methylglutaryl-coenzyme A; NSAID; nonsteroidal anti-inflammatory drug; PPI; proton pump i